TIL Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: TIL Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $3.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

TIL Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $3.4M Trade | TransData Nexus

TIL Healthcare Private Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $3.4M Total Trade · DGFT Verified

TIL Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.4M across 2 products in 1 therapeutic categories. Based on 70 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Amino ($3.4M), Probiotics ($34.3K), .

TIL Healthcare Private Limited — Export Portfolio & Destination Treemap

TIL Healthcare Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is TIL Healthcare Private Limited? — Company Overview & Market Position

TIL Healthcare Private Limited, established on January 25, 1991, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U24231TN1991PTC020206. As of March 31, 2024, TIL Healthcare reported an authorized capital of ₹5.00 crore and a paid-up capital of ₹2.31 crore. The company employs approximately 230 professionals, reflecting its commitment to quality and innovation in the pharmaceutical sector.

TIL Healthcare specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Over the years, the company has expanded its global footprint, exporting products to over 54 countries across Africa, Asia, Latin America, Europe, and the CIS region. This extensive reach underscores TIL Healthcare's dedication to enhancing global health outcomes through high-quality pharmaceutical products.

What Does TIL Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Amino$3.4M 2

Product Portfolio — Top 2 by Export Value

TIL Healthcare Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amino	Nutritional Supplements	$3.4M	67	1.0%	11
2	Probiotics	Nutritional Supplements	$34.3K	3	0.3%	6

TIL Healthcare Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $3.4M. The top category is Nutritional Supplements (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

TIL Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

TIL Healthcare operates multiple state-of-the-art manufacturing facilities, including a significant plant in the Sri City Special Economic Zone (SEZ) in Tada, Andhra Pradesh. This facility has undergone substantial expansion, tripling its capacity to meet the growing global demand for its products. The manufacturing plants are approved by various health regulatory authorities, including EU-GMP, TGA Australia, FDA Ghana, and NAFDAC Nigeria, along with cGMP and ISO certifications.

The company's manufacturing capabilities encompass a diverse range of dosage forms, such as tablets, capsules, soft gels, liquids, powders, injectables, suppositories, effervescents, and drops. This versatility enables TIL Healthcare to cater to a wide array of therapeutic needs, reinforcing its position as a comprehensive pharmaceutical manufacturer.

3Key Leadership

TIL Healthcare is led by Managing Director Mr. Kapil Jhaver, who has been instrumental in steering the company towards significant growth and global expansion. Under his leadership, the company has achieved notable milestones, including the expansion of its manufacturing facilities and the establishment of a strong presence in over 54 countries.

The company's leadership team also includes Director Mr. Rangarajan Vijayaragavan, who has been associated with TIL Healthcare since March 17, 2022. Additionally, Mr. Kapil Jhaver serves as an Additional Director, contributing to the strategic direction and operational excellence of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does TIL Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

TIL Healthcare has established a robust presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold certifications from esteemed regulatory bodies such as the European Union's Good Manufacturing Practice (EU GMP) and the Therapeutic Goods Administration (TGA) of Australia. These certifications attest to the company's adherence to stringent quality standards required for market access in these regions.

In the United States, TIL Healthcare has made significant strides by obtaining FDA approvals for its manufacturing facilities and product registrations. This achievement facilitates the company's entry into the U.S. market, allowing it to supply high-quality pharmaceutical products to meet the needs of American consumers.

The company's commitment to regulatory compliance is further demonstrated by its successful submissions to Denmark and Hungary in 2025, expanding its reach within the European market. These efforts reflect TIL Healthcare's dedication to meeting the diverse regulatory requirements of various international markets.

2Emerging Markets

TIL Healthcare has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia, exporting its products to over 54 countries across these regions. The company's adherence to international quality standards, as evidenced by certifications such as EU GMP and TGA, has facilitated its acceptance in these markets. Additionally, TIL Healthcare's commitment to corporate social responsibility (CSR) initiatives, including the establishment of the TIL Foundation in 2019, demonstrates its dedication to contributing positively to the communities it serves.

TIL Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

TIL Healthcare has achieved FDA facility registrations, enabling it to manufacture and export pharmaceutical products to the United States. The company's commitment to quality is further demonstrated by its adherence to current Good Manufacturing Practice (cGMP) standards, ensuring that its products meet the stringent requirements set by the FDA. While specific details regarding approved Abbreviated New Drug Applications (ANDAs) and Drug Master File (DMF) filings are not publicly disclosed, the company's FDA registrations indicate a proactive approach to compliance and market access.

2WHO & EU GMP

TIL Healthcare's manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practice (WHO GMP) and the European Union's Good Manufacturing Practice (EU GMP). These certifications affirm the company's adherence to international quality standards, facilitating its entry into various global markets. The EU GMP certification, obtained in 2023, underscores the company's commitment to maintaining high-quality manufacturing processes.

3CDSCO & Indian Regulatory

TIL Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

TIL Healthcare operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. While specific market share data for TIL Healthcare's products is not publicly disclosed, the company's extensive product portfolio and global presence position it as a significant player in the market. The company's adherence to international quality standards, as evidenced by certifications such as EU GMP and TGA, enhances its competitiveness in regulated markets.

2Key Differentiators

TIL Healthcare's key differentiators include its diverse product portfolio, encompassing various dosage forms such as tablets, capsules, injectables, liquids, powders, and effervescents. The company's commitment to quality is demonstrated by its adherence to international standards, with certifications from EU GMP, TGA, and ISO. Additionally, TIL Healthcare's strategic focus on both regulated and emerging markets allows it to leverage growth opportunities across different regions.

3Strategic Position

TIL Healthcare's current strategic direction emphasizes the expansion of its product portfolio and market presence. The company's focus on both finished pharmaceutical formulations and contract manufacturing services (CDMO) enables it to cater to a wide range of client needs. Looking ahead, TIL Healthcare aims to strengthen its position in existing markets while exploring new opportunities, particularly in emerging regions, to drive sustainable growth and innovation.

Buyer Due Diligence Brief — Evaluating TIL Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

TIL Healthcare has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $3.4 million USD and 70 shipments across two products in 2022-2026. The company's adherence to international quality standards, as evidenced by certifications such as EU GMP and TGA, indicates a high level of reliability. The absence of publicly available records indicating regulatory non-compliance further supports the company's reputation as a dependable supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's FDA facility registration to ensure compliance with U.S. regulations.

EU GMP Certification: Verify the EU GMP certification to ensure adherence to European manufacturing standards.

Frequently Asked Questions — TIL Healthcare Private Limited

How many pharmaceutical products does TIL Healthcare Private Limited export from India?

TIL Healthcare Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Amino ($3.4M), Probiotics ($34.3K). Total export value is $3.4M.

What is TIL Healthcare Private Limited's total pharmaceutical export value?

TIL Healthcare Private Limited's total pharmaceutical export value is $3.4M, based on 70 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does TIL Healthcare Private Limited cover?

TIL Healthcare Private Limited exports across 1 therapeutic categories. The largest are Nutritional Supplements (100.0%, 2 products).

Get Full TIL Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.